Healthcare Services

Increasing Adoption Of Rising Sunburn Incidents Fuel Growth Of The Market Is Influencing The Advanced Melanoma Market

May 27, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Expected Market Size Of The Advanced Melanoma Market In 2026 And How Much Will It Reach By 2030?

The advanced melanoma market has seen robust expansion over recent years. It is anticipated to increase from $4.12 billion in 2025 to $4.5 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.3%. This historical growth can be linked to factors such as scarce treatment options for advanced stages, increasing rates of melanoma incidence, the development of hospital and oncology center infrastructure, heightened awareness regarding skin cancer, and the implementation of conventional chemotherapy and biological therapies.

The advanced melanoma market is projected to experience robust expansion over the coming years. Its valuation is anticipated to reach $6.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.1%. This predicted growth stems from several factors, including advancements in immune checkpoint inhibitors, a rise in the application of targeted therapies such as BRAF and MEK inhibitors, the wider adoption of personalized medicine strategies, increased investment in melanoma research, and the integration of digital health and patient monitoring systems. Key developments expected during this period involve the increasing uptake of immunotherapy and targeted treatments, a greater reliance on biomarker-based approaches for treatment selection, enhanced capabilities within hospitals and oncology centers, a sharper focus on tools for early detection and diagnosis, and an increase in clinical trials and research efforts concerning advanced melanoma.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21088&type=smp

What Primary Factors Are Fueling The Expansion Of The Advanced Melanoma Market?

The projected growth of the advanced melanoma market is expected to be driven by the increasing occurrence of severe sunburn cases. These severe sunburns are characterized as intense skin burns caused by excessive exposure to ultraviolet (UV) radiation, leading to symptoms like redness, pain, swelling, and sometimes blistering. The rising number of severe sunburn incidents stems from prolonged exposure to ultraviolet (UV) radiation, insufficient sun protection practices, increased outdoor activities during peak UV hours, and escalating temperatures due to climate change. Specifically, severe sunburns, especially those that recur or happen early in life, lead to DNA damage within skin cells, which can result in genetic mutations that trigger melanoma. For example, according to Melanoma Focus, a UK-based charity dedicated to supporting the melanoma community, in May 2024, there were 201 hospital admissions due to sunburn during 2022-23, including 89 children and 25 babies under one-year-old. Additionally, 66% of UK adults aged 16-65 recalled getting sunburned as children, and 65% experienced severe sunburn with blisters at least once. This figure increased to 77% for individuals with light, pale, or white skin. Therefore, the growing number of severe sunburn cases is propelling the expansion of the advanced melanoma market.

Which Segment-Based Categories Are Covered In The Advanced Melanoma Market?

The advanced melanoma market covered in this report is segmented –

1) By Therapeutics: Chemotherapy, Biological Therapy, Targeted Therapy, Immune Therapy

2) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy

3) By End-User: Hospitals, Cancer Research Centres, Academic Institutes, Diagnostic Centers, Ambulatory Surgical Centers, Other End Users

Subsegments:

1) By Chemotherapy: Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors, Other Chemotherapy Drugs

2) By Biological Therapy: Monoclonal Antibodies, Interferons, Interleukins

3) By Targeted Therapy: BRAF Inhibitors, MEK Inhibitors, KIT Inhibitors, Other Targeted Therapies

4) By Immune Therapy: Immune Checkpoint Inhibitors, Cancer Vaccines, Oncolytic Virus Therapy, Adoptive Cell Transfer

Which Trends Are Expected To Shape The Advanced Melanoma Market?

Leading companies within the advanced melanoma market are prioritizing the creation of novel solutions, including personalized vaccines. These innovations aim to enhance treatment effectiveness, combat resistance, and offer tailored therapies, ultimately leading to improved patient results and extended lifespans. Specifically, a personalized vaccine for advanced melanoma constitutes a cancer therapy customized for an individual, leveraging the distinct genetic mutations present in their tumor. An illustrative case occurred in April 2023, when Merck & Co. Inc., alongside Moderna Inc., was granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA). This was for their experimental personalized mRNA cancer vaccine, mRNA-4157/V940, intended for use with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab). This combination targets the adjuvant treatment of individuals with high-risk stage III/IV melanoma after complete resection. This personalized cancer vaccine, mRNA-4157/V940, consists of a single synthetic mRNA that codes for as many as 34 neoantigens, with its design and production being based on the distinct mutational signature of an individual patient’s tumor.

Who Are The Leading Firms Participating In The Advanced Melanoma Market?

Major companies operating in the advanced melanoma market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca AG, Novartis AG, Amgen Inc., BioNTech SE, Regeneron Pharmaceuticals, Genentech Inc., Exelixis Inc., Dynavax Technologies, Replimune Group, Immunocore Holdings plc, Xencor Inc., Agenus Inc., Nektar Therapeutics, Iovance Biotherapeutics, Adaptimmune Therapeutics, Immutep Ltd., Lytix Biopharma

Access The Complete Advanced Melanoma Market Report:

https://www.thebusinessresearchcompany.com/report/advanced-melanoma-global-market-report

Which Region Holds The Largest Share In The Advanced Melanoma Market?

North America was the largest region in the advanced melanoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced melanoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Advanced Melanoma Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/customise?id=21088&type=smp

Browse Through More Reports Similar to the Global Advanced Melanoma Market 2026, By The Business Research Company

Malignant Melanoma Treatment Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/malignant-melanoma-treatment-global-market-report

Melanoma Drugs Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/melanoma-drugs-global-market-report

Metastatic Melanoma Therapeutics Global Market Report 2026

https://www.thebusinessresearchcompany.com/report/metastatic-melanoma-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795